Earlier this month, Cephalon Inc. (CEPH) announced that it has settled its patent infringement case with Barr Pharmaceuticals, which is now owned by Teva Pharmaceutical (TEVA). Barr was looking to market a generic version of Cephalon’s cancer pain management drug, Fentora.   As per the terms of the agreement, Barr has been granted a non-exclusive, royalty-free right to sell a generic version of Fentora in October 2018. However, if a generic version of Fentora enters the market prior to that date, Barr will be allowed to launch its generic version provided the other generic company does not enjoy marketing exclusivity. According to Cephalon, Fentora’s patent is not set to expire before 2019.   While we are pleased to hear about this settlement agreement with Barr, we note that another major generic player, Watson Pharmaceuticals (WPI), is also seeking to bring a generic version of Fentora to market....

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday November 17, 2009

DrStockPick.com Stock Report!

PWRM, NGSX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday November 17, 2009 are:

**************************************************************

NGSX, NeurogesX, Inc.

NGSX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies.

** The U.S. Food and Drug Administration (FDA) has approved NGSX’s Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia, the nerve pain which can follow an attack of shingles.

NGSX’s Qutenza delivers a synthetic form of capsaicin, the substance in chili peppers that gives them their heat sensation, through a dermal delivery system, providing up to 12 weeks of reduced

...

Imaging3 Inc. is a leading provider of advanced technology medical imaging devices. Founded in 1993 by Dean Janes, the Company has developed a breakthrough medical imaging device. This device produces 3D medical diagnostic images of virtually any part of the human body in real-time. Imaging3 Inc. trades on the OTC Bulletin Board. They have their headquarters in Burbank, California.

The 3D images, instantly constructed in real-time, are useable for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Healthcare workers using Imaging3 devices will be able to instantly view 3D, high-resolution images. The Company intends to use their existing base of operations and channels of distribution to launch their new medical imaging devices business, based on this Imaging3 Technology.

The Dominion Volumetric Imaging Scanner (DVIS) is a patented mobile fluoroscopy technology. This product can produce a

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday October 29, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc. (OTC Bulletin Board: CVAT) is pleased to announce a 3-for-1 forward stock split effective at the market open Thursday, October 29th. CTI is a world leader in the development of technologies that represent a quantum leap over existing processing methods for a wide variety of applications and industries. Positioned to provide licensing and sales of its technology which can be applied to virtually every industrial fluid that requires complex molecular bonding, including large-scale water purification, removing

...

Kimberly-Clark Corporation (KMB) reported strong third quarter results with earnings of $1.40 per share. Earnings were well above the Zacks Consensus Estimate of $1.04 and up a record 37.3% year over year. Profits were driven by higher prices and lower commodity and energy costs. However, net sales for the quarter declined 1.7% year-over-year to $4.9 billion, due to the adverse effect of weaker foreign currency exchange rates and flat volumes, which was more than offset by an organic sales growth of about 3%. In addition, the weak economic environment, especially in North America, impacted the top-line. Three of the four operating divisions: Personal Care (-0.7%), Consumer Tissue (-5.0%) and K-C (-4.5%) experienced revenue declines, while the Health Care segment increased 15.8% year-over-year. The Personal Care segment was impacted by negative currency translations and volume declines in Huggies diapers. Sales in the Consumer Tissue segment were down ...

Recently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant for the treatment of opioid-induced constipation. The data was presented at the American Academy of Pain Management's 20th Annual Clinical Meeting in Phoenix, AZ. The drug met the primary endpoint of increase in spontaneous bowel movement over the baseline period along with no reduction of opioid-mediated analgesia in any dose groups. In addition, NKTR-118 was well tolerated, the common side effects being dose-dependent gastrointestinal-related effects. In September, AstraZeneca (AZN) had entered into a licensing deal with Nektar Therapeutics for two of its pipeline candidates, NKTR-118 and NKTR-119. While the former is a phase II trial candidate, the latter, in its early stage of development, is intended to treat pain without constipation as a side effect. We believe the deal will be beneficial to both the companies. In addition to receiving ...

Kimberly-Clark Corp. (KMB) announced that it acquired Baylis Medical Co.'s pain management business. The acquisition also includes a number of innovative, minimally-invasive radio-frequency pain management products.

Baylis was founded by Gloria Baylis (a registered nurse) in Montreal in 1986. In addition, to pain management products, the company also makes high-tech medical devices for cardiology and radiology.

The acquisition is believed to improve the competitive position of the company’s Health Care segment in the $2 billion global market for minimally invasive chronic spinal pain management. 

However, the financial terms of the transaction were not disclosed. Since 2001, Kimberly Clark's Health Care division has been the exclusive distributor of Baylis Medical's pain management products in the U.S.

Management stated that the Baylis pain management business acquisition is consistent with the company’s global business strategy to invest in the higher-growth, higher-margin medical device market. This transaction will enable Kimberly-Clark to accelerate its growth in the pain

...

Odyssey Healthcare, Inc. (ODSY) surprised on estimates 3 out of the last 4 quarters by an average of 29.37%. The hospice provider is cheap, trading with a PEG ratio of just 0.91.

Company Description

Odyssey Healthcare provides hospice care in more than 30 states for terminally ill patients and their families. ODSY offers pain management and addresses the psychological and spiritual needs of the patients and their families.

Odyssey uses nurses, doctors, home healthcare aides, social workers, chaplains, bereavement counselors and trained volunteers to provide care in patients' homes, nursing homes or assisted living facilities.

Odyssey Surprised in the Second Quarter by 17.39%

On Aug 4, Odyssey reported second quarter results that beat the Zacks Consensus Estimate by 4 cents. Earnings per share increased 125% to 27 cents from 12 cents in the year ago quarter. The Zacks Consensus Estimate called for 23 cents.

Net patient service revenue continued

...

Recently, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced constipation, the latter, in early stage of development, is intended to treat pain without constipation side effects. Nektar will receive an upfront payment of $125 million for both the candidates. In addition, for NKTR-118, Nektar has the potential to receive $235 million of milestone payments on achieving certain regulatory milestones, as well as additional tiered sales milestone payments of up to $375 million if the drug succeeds in recording strong sales. The company will also receive double-digit royalty payments on global sales of the drug. For NKTR-119, Nektar is also supposed to receive milestone and royalty payments. Per the deal, AstraZeneca will carry on the development of both the ...